NeoGenomics (NASDAQ:NEO) had its price target increased by analysts at Royal Bank of Canada from $23.00 to $24.00 in a note issued to investors on Tuesday. The brokerage currently has an “outperform” rating on the medical research company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 181.69% from the stock’s current price.
A number of other analysts also recently issued reports on the company. Scotiabank lifted their price target on NeoGenomics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday. ValuEngine downgraded NeoGenomics from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. BidaskClub raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Finally, CIBC set a $19.00 price target on NeoGenomics and gave the stock a “neutral” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $17.29.
Shares of NeoGenomics (NASDAQ NEO) traded down $0.19 during midday trading on Tuesday, reaching $8.52. The company’s stock had a trading volume of 187,622 shares, compared to its average volume of 417,833. The stock has a market cap of $700.37, a P/E ratio of -60.85, a price-to-earnings-growth ratio of 4.84 and a beta of 0.47. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99. NeoGenomics has a 12 month low of $7.08 and a 12 month high of $11.63.
Several institutional investors have recently bought and sold shares of NEO. Janus Henderson Group PLC lifted its holdings in shares of NeoGenomics by 50.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock valued at $38,562,000 after purchasing an additional 1,159,888 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of NeoGenomics in the 4th quarter valued at about $6,848,000. Russell Investments Group Ltd. lifted its holdings in shares of NeoGenomics by 25.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,496,623 shares of the medical research company’s stock valued at $27,786,000 after purchasing an additional 499,913 shares during the last quarter. Columbus Circle Investors purchased a new stake in shares of NeoGenomics in the 3rd quarter valued at about $4,779,000. Finally, Segall Bryant & Hamill LLC lifted its holdings in shares of NeoGenomics by 318.0% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 374,068 shares of the medical research company’s stock valued at $4,163,000 after purchasing an additional 284,572 shares during the last quarter. 84.72% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3260112/neogenomics-neo-price-target-raised-to-24-00-at-royal-bank-of-canada.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.